NASDAQ:ZBIO Zenas BioPharma (ZBIO) Stock Price, News & Analysis $15.90 +1.00 (+6.71%) As of 08/12/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Zenas BioPharma Stock (NASDAQ:ZBIO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Zenas BioPharma alerts:Sign Up Key Stats Today's Range$14.51▼$16.1750-Day Range$9.14▼$16.8152-Week Range$5.83▼$26.25Volume98,042 shsAverage Volume138,024 shsMarket Capitalization$665.16 millionP/E RatioN/ADividend YieldN/APrice Target$36.67Consensus RatingBuy Company Overview Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA. Read More Zenas BioPharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks30th Percentile Overall ScoreZBIO MarketRank™: Zenas BioPharma scored higher than 30% of companies evaluated by MarketBeat, and ranked 806th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingZenas BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageZenas BioPharma has only been the subject of 2 research reports in the past 90 days.Read more about Zenas BioPharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Zenas BioPharma is -4.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zenas BioPharma is -4.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZenas BioPharma has a P/B Ratio of 2.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Zenas BioPharma's valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ZBIO. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldZenas BioPharma does not currently pay a dividend.Dividend GrowthZenas BioPharma does not have a long track record of dividend growth.Read more about Zenas BioPharma's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for ZBIO. News and Social Media1.9 / 5News Sentiment0.36 News SentimentZenas BioPharma has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Zenas BioPharma this week, compared to 11 articles on an average week.Search InterestOnly 1 people have searched for ZBIO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Zenas BioPharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Zenas BioPharma insiders have not sold or bought any company stock.Percentage Held by Insiders16.50% of the stock of Zenas BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Zenas BioPharma's insider trading history. Receive ZBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zenas BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ZBIO Stock News HeadlinesZenas BioPharma Reports Q2 2025 Financial ResultsAugust 13 at 2:14 AM | tipranks.comZenas BioPharma expects cash to fund operations into Q4 of 2026August 12 at 10:42 PM | msn.comYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…August 13 at 2:00 AM | Crypto 101 Media (Ad)Zenas BioPharma reports Q2 EPS ($1.25) vs ($24.23) last yearAugust 12 at 4:31 PM | msn.comZenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate UpdatesAugust 12 at 7:05 AM | globenewswire.com3 Highly Shorted Stocks That Could Be the Next Wall Street SensationsAugust 2, 2025 | msn.comZenas Biopharma: A Risky Buy On Upcoming Data Readouts In IgG4, MSJuly 28, 2025 | seekingalpha.comInnovative Approach and Upcoming Catalysts Drive Buy Rating for Zenas BioPharmaJuly 3, 2025 | tipranks.comSee More Headlines ZBIO Stock Analysis - Frequently Asked Questions How have ZBIO shares performed this year? Zenas BioPharma's stock was trading at $7.90 on January 1st, 2025. Since then, ZBIO shares have increased by 101.3% and is now trading at $15.90. How were Zenas BioPharma's earnings last quarter? Zenas BioPharma, Inc. (NASDAQ:ZBIO) issued its earnings results on Tuesday, August, 12th. The company reported ($1.25) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by $0.23. When did Zenas BioPharma IPO? Zenas BioPharma (ZBIO) raised $225 million in an initial public offering on Friday, September 13th 2024. The company issued 13,235,294 shares at a price of $17.00 per share. Who are Zenas BioPharma's major shareholders? Top institutional shareholders of Zenas BioPharma include Geode Capital Management LLC (0.89%), Rhumbline Advisers (0.05%), Intech Investment Management LLC (0.03%) and PNC Financial Services Group Inc. (0.02%). How do I buy shares of Zenas BioPharma? Shares of ZBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Zenas BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zenas BioPharma investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Trade Desk (TTD), Advanced Micro Devices (AMD), Biosig Technologies (BSGM), Ford Motor (F) and Genius Sports (GENI). Company Calendar Last Earnings8/12/2025Today8/13/2025Next Earnings (Estimated)8/21/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:ZBIO Previous SymbolNASDAQ:ZBIO CIK1953926 WebN/A Phone(857) 271-2954FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Zenas BioPharma$36.67 High Price Target$45.00 Low Price Target$30.00 Potential Upside/Downside+130.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio6.47 Quick Ratio6.47 Sales & Book Value Annual Sales$15 million Price / Sales44.34 Cash FlowN/A Price / Cash FlowN/A Book Value$7.48 per share Price / Book2.13Miscellaneous Outstanding Shares41,834,000Free Float34,931,000Market Cap$665.16 million OptionableN/A BetaN/A Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:ZBIO) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zenas BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zenas BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.